quilizumab   Click here for help

GtoPdb Ligand ID: 8998

Synonyms: 47H4 v5 hulgG1 [4] | MEMP1972A | RG-7449
Immunopharmacology Ligand
Compound class: Antibody
Comment: Quilizumab is a humanized IgG1κ investigational monoclonal antibody designed to bind the M1' segment of membrane-bound immunoglobulin E (mIgE), which is part of the B-cell receptor (BCR) on B cells [1].
Peptide sequences and 3D structural information for this antibody are available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals 100% matches with sequences claimed in patent US8071097 B2 [4].
Click here for help
1. Gauvreau GM, Harris JM, Boulet LP, Scheerens H, Fitzgerald JM, Putnam WS, Cockcroft DW, Davis BE, Leigh R, Zheng Y et al.. (2014)
Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production.
Sci Transl Med, 6 (243): 243ra85. [PMID:24990880]
2. Kolkhir P, Altrichter S, Munoz M, Hawro T, Maurer M. (2020)
New treatments for chronic urticaria.
Ann Allergy Asthma Immunol, 124 (1): 2-12. [PMID:31446134]
3. Pennington LF, Gasser P, Brigger D, Guntern P, Eggel A, Jardetzky TS. (2021)
Structure-guided design of ultrapotent disruptive IgE inhibitors to rapidly terminate acute allergic reactions.
J Allergy Clin Immunol, 148 (4): 1049-1060. [PMID:33991582]
4. Wu L, Balazs M, Brightbill H, Chan A, Chen Y, Chuntharapai A, Dennis M, Wong T. (2011)
Apoptotic anti-IgE antibodies.
Patent number: US8071097 B2. Assignee: Genentech, Inc.. Priority date: 22/03/2007. Publication date: 06/12/2011.